/IRBS

IRBS Stock - IR Biosciences Holdings Inc.

Q: What is the analyst price target for IRBS?

Analyst price target information is not currently available for IRBS.

Q: What is IRBS's market cap?

Market capitalization information is not currently available for IRBS.

Healthcare|Biotechnology|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Jul 15

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for IRBS

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2006

FY2007

FY2008

FY2009

FY2010

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta5.01

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2010	FY2009	FY2008	FY2007	FY2006
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-2,860,000	$-3,126,000	$-5,024,000	$-5,516,000	$-2,445,000
Net Income	$-5,278,000	$-6,463,000	$-5,807,000	$-5,464,000	$-1,486,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-0.31	$-0.49	$-0.49	$-0.50	$-0.20

Company Overview

IR BioSciences Holdings, Inc. operates as a development stage biotechnology company in the United States. The company, through its subsidiary, ImmuneRegen BioSciences, Inc., engages in the research and development of therapies in the areas of pulmonary fibrosis, influenza infection, and radiation-induced Neutropenia. It is involved in the development of Homspera, and its derivates Radilex and Viprovex, for human stem cell stimulation, immune system stimulation and anti-infective activity, vaccine adjuvancy, and wound healing. IR BioSciences Holdings, Inc. was founded in 1999 and is headquartered in Scottsdale, Arizona.

Frequently Asked Questions about IRBS

What is IRBS's current stock price?

IR Biosciences Holdings Inc. (IRBS) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for IRBS?

No analyst price targets are currently available for this stock.

What sector is IR Biosciences Holdings Inc. in?

IR Biosciences Holdings Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.

What is IRBS's market cap?

IR Biosciences Holdings Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does IRBS pay dividends?

No, IR Biosciences Holdings Inc. does not currently pay a dividend to shareholders.